UCB (XBRU:UCB) Institutional Ownership : 33.02% (As of Apr. 30, 2024)

View and export this data going back to 1988. Start your Free Trial

What is UCB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, UCB's institutional ownership is 33.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, UCB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, UCB's Float Percentage Of Total Shares Outstanding is 0.00%.

UCB Institutional Ownership Historical Data

The historical data trend for UCB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Institutional Ownership Chart

UCB Historical Data

The historical data trend for UCB can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	31.71	31.58	31.38	31.17	31.30	31.37	30.35	31.19	31.88	33.02

UCB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

UCB (XBRU:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (XBRU:UCB) Headlines

No Headlines